Compare IDR & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IDR | BWAY |
|---|---|---|
| Founded | 1996 | 2003 |
| Country | United States | Israel |
| Employees | N/A | 129 |
| Industry | Precious Metals | Medical/Dental Instruments |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 684.7M | 674.2M |
| IPO Year | 2000 | N/A |
| Metric | IDR | BWAY |
|---|---|---|
| Price | $42.54 | $16.41 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $13.25 |
| AVG Volume (30 Days) | ★ 218.8K | 131.1K |
| Earning Date | 05-13-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 70.15 | N/A |
| EPS | ★ 1.14 | N/A |
| Revenue | ★ $42,406,253.00 | N/A |
| Revenue This Year | $25.52 | $309.69 |
| Revenue Next Year | N/A | $26.21 |
| P/E Ratio | ★ $38.29 | $81.98 |
| Revenue Growth | ★ 64.59 | N/A |
| 52 Week Low | $12.25 | $8.61 |
| 52 Week High | $54.70 | $26.63 |
| Indicator | IDR | BWAY |
|---|---|---|
| Relative Strength Index (RSI) | 57.22 | 56.96 |
| Support Level | $41.55 | $14.56 |
| Resistance Level | $46.85 | $16.63 |
| Average True Range (ATR) | 2.33 | 0.62 |
| MACD | -0.04 | 0.22 |
| Stochastic Oscillator | 48.36 | 71.03 |
Idaho Strategic Resources Inc is a vertically integrated, operating junior mining company. The Company's primary business is exploring for, developing, and extracting gold, and to a lesser extent, silver, and base metal mineral resources in the greater Coeur d'Alene Mining District of North Idaho. The Company produces gold at the Golden Chest Mine located in the Murray Gold Belt area of the world-class Coeur d'Alene Mining District, north of the prolific Silver Valley.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.